Compare SAM & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAM | MLTX |
|---|---|---|
| Founded | 1984 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 1996 | 2020 |
| Metric | SAM | MLTX |
|---|---|---|
| Price | $163.81 | $12.07 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 12 |
| Target Price | ★ $233.70 | $27.50 |
| AVG Volume (30 Days) | 169.7K | ★ 1.5M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.45 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,964,994,000.00 | N/A |
| Revenue This Year | $1.02 | N/A |
| Revenue Next Year | $1.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $158.68 | $5.95 |
| 52 Week High | $264.46 | $23.29 |
| Indicator | SAM | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.00 | 30.51 |
| Support Level | $162.58 | $11.88 |
| Resistance Level | $189.24 | $19.24 |
| Average True Range (ATR) | 6.57 | 0.78 |
| MACD | -0.32 | 0.05 |
| Stochastic Oscillator | 22.61 | 7.16 |
Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.